Summary
IDEXX Laboratories, Inc. reported solid revenue growth for the second quarter of 2024, driven primarily by its Companion Animal Group (CAG) segment, which saw increases in diagnostics recurring revenue, supported by price realization and volume growth. Overall revenue for the quarter increased by 6.4% year-over-year to $1.004 billion. While operating income saw a decline of 10.9% to $263.8 million, this was largely due to a significant $61.5 million expense related to an ongoing litigation matter. Excluding this one-time charge, the company demonstrated continued operational strength and profitability. The company's balance sheet remains robust, with total assets growing to $3.41 billion. While cash and cash equivalents decreased slightly to $401.6 million from $453.9 million at the end of 2023, this was primarily due to strategic uses of cash, including significant share repurchases totaling $370.3 million in the first six months of 2024. The company maintains substantial liquidity with $998.5 million in unused borrowing capacity under its credit facility, indicating strong financial flexibility. Investors should note the ongoing litigation accrual as a significant factor influencing near-term profitability.
Financial Highlights
53 data points| Revenue | $1.00B |
| Cost of Revenue | $384.42M |
| Gross Profit | $619.16M |
| R&D Expenses | $55.45M |
| Operating Expenses | $355.36M |
| Operating Income | $263.80M |
| Net Income | $203.30M |
| EPS (Basic) | $2.46 |
| EPS (Diluted) | $2.44 |
| Shares Outstanding (Basic) | 82.63M |
| Shares Outstanding (Diluted) | 83.39M |
Key Highlights
- 1Total revenue increased by 6.4% to $1.004 billion for the second quarter of 2024 compared to the prior year, driven by strong performance in the Companion Animal Group (CAG).
- 2CAG segment revenue grew by 6.4% to $922.3 million, with CAG Diagnostics recurring revenue showing a 6.0% increase.
- 3Operating income decreased by 10.9% to $263.8 million, primarily due to a $61.5 million accrual for an ongoing litigation matter.
- 4Net income for the quarter was $203.3 million, a slight decrease from $224.2 million in the prior year, impacted by the litigation expense.
- 5Cash and cash equivalents stood at $401.6 million at the end of the quarter, with $998.5 million in available borrowing capacity under the credit facility.
- 6The company repurchased $370.3 million of its common stock in the first six months of 2024, demonstrating a commitment to returning capital to shareholders.
- 7The company increased its accrual for an ongoing litigation matter by $61.5 million, bringing the total accrual to $89.0 million, which impacted current period earnings.